Amneal Pharmaceuticals (NYSE:AMRX) Stock Price Down 6.4%

Amneal Pharmaceuticals Inc (NYSE:AMRX) shares traded down 6.4% during mid-day trading on Friday . The stock traded as low as $6.84 and last traded at $6.87. 932,021 shares changed hands during mid-day trading, a decline of 9% from the average session volume of 1,022,955 shares. The stock had previously closed at $7.34.

Several analysts have issued reports on the company. Cantor Fitzgerald lowered their target price on Amneal Pharmaceuticals from $35.00 to $14.00 and set an “overweight” rating on the stock in a research note on Wednesday. Barclays began coverage on Amneal Pharmaceuticals in a research note on Tuesday, June 11th. They issued an “equal weight” rating and a $9.00 target price on the stock. Raymond James upgraded Amneal Pharmaceuticals from a “market perform” rating to a “strong-buy” rating and set a $13.00 price objective on the stock in a research note on Tuesday, May 21st. They noted that the move was a valuation call. BMO Capital Markets decreased their price objective on Amneal Pharmaceuticals from $14.00 to $13.00 and set a “market perform” rating on the stock in a research note on Friday, May 10th. Finally, Zacks Investment Research upgraded Amneal Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Wednesday, May 8th. One research analyst has rated the stock with a sell rating, seven have given a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $16.73.

The company has a debt-to-equity ratio of 3.44, a current ratio of 2.11 and a quick ratio of 1.37. The company has a market cap of $2.05 billion, a PE ratio of 7.39, a price-to-earnings-growth ratio of 0.42 and a beta of 1.63.

Amneal Pharmaceuticals (NYSE:AMRX) last released its quarterly earnings data on Thursday, May 9th. The company reported $0.11 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.07). Amneal Pharmaceuticals had a negative net margin of 3.75% and a positive return on equity of 32.14%. The company had revenue of $446.00 million for the quarter, compared to the consensus estimate of $438.18 million. The company’s revenue for the quarter was up 4.9% on a year-over-year basis. On average, equities analysts expect that Amneal Pharmaceuticals Inc will post 0.91 EPS for the current year.

In other Amneal Pharmaceuticals news, SVP Pradeep Bhadauria bought 7,000 shares of the firm’s stock in a transaction on Wednesday, May 15th. The shares were acquired at an average cost of $8.48 per share, for a total transaction of $59,360.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP Andrew S. Boyer bought 19,000 shares of the firm’s stock in a transaction on Monday, May 13th. The stock was acquired at an average price of $9.46 per share, for a total transaction of $179,740.00. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 41,000 shares of company stock worth $387,300. 26.34% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in AMRX. Cresset Asset Management LLC bought a new position in Amneal Pharmaceuticals in the 1st quarter worth about $29,000. Bessemer Group Inc. bought a new position in Amneal Pharmaceuticals in the 4th quarter worth about $34,000. NumerixS Investment Technologies Inc increased its stake in Amneal Pharmaceuticals by 52.1% in the 1st quarter. NumerixS Investment Technologies Inc now owns 3,052 shares of the company’s stock worth $42,000 after acquiring an additional 1,045 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Amneal Pharmaceuticals by 28.3% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,700 shares of the company’s stock worth $91,000 after acquiring an additional 1,477 shares during the last quarter. Finally, Quantamental Technologies LLC increased its stake in Amneal Pharmaceuticals by 34.0% in the 1st quarter. Quantamental Technologies LLC now owns 6,700 shares of the company’s stock worth $95,000 after acquiring an additional 1,700 shares during the last quarter. Institutional investors and hedge funds own 36.05% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Amneal Pharmaceuticals (NYSE:AMRX) Stock Price Down 6.4%” was reported by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this news story can be read at https://www.com-unik.info/2019/06/16/amneal-pharmaceuticals-nyseamrx-stock-price-down-6-4.html.

Amneal Pharmaceuticals Company Profile (NYSE:AMRX)

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.

Recommended Story: What are Bollinger Bands?

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit